Remove 2028 Remove Competition Remove Leads
article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028.

Pharma 186
article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

According to GlobalData’s report, Coronavirus Disease 2019 (Covid-19) Analyst Consensus Sales Analysis and Forecast, H1 2022 , Comirnaty is the leading prophylactic Covid-19 vaccine and recorded sales of $41.3bn in 2021. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%

Sales 108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program.

article thumbnail

H2 2022 to see the decline of Covid-19 vaccines as forecasts decrease

Pharmaceutical Technology

These are forecast to generate $264 billion in sales between 2021 and 2028. Comirnaty, which was first approved in the UK by an Emergency Use Approval (EUA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 2, 2020, is currently the leading prophylactic vaccine with 2021 sales of $41.5

Sales 52
article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. trillion in the Q1 of 2023 to $3.56

article thumbnail

The EU AI Act: will regulation drive life science innovation away from Europe?

European Pharmaceutical Review

The absence of adequate infrastructure mirrors the issues encountered by MDR and IVDR, leading to delays because notified bodies were not adequately prepared and did not have adequate capacity. Michael has nearly 20 years of knowledge and experience leading localised and global teams in regulatory affairs and quality assurance.

article thumbnail

Emerging Trends in Orthopedic Medical Device Industry

Medico Reach

million by 2028. However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. The US-based Enovis is leading this new development.

Medical 98